From FDA labels and ClinicalTrials.gov

Can teens and children take a GLP-1?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

FDA has approved Wegovy, Trulicity, Saxenda, Victoza and Mounjaro for this, in the words of each label below. STEP TEENS (Semaglutide): At week 68, BMI fell 16.1% on semaglutide against a rise of 0.6% on placebo in adolescents with obesity. Stomach side effects were more common (62% against 42%), and 4% on semaglutide had gallstones against none on placebo. N Engl J Med, 2022 (pubmed.ncbi.nlm.nih.gov/36322838). ClinicalTrials.gov lists 65 trials of these medicines on it: 21 with posted results and 21 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 17, 2026.

FDA approved

What each label says on teens and children

The approved use, word for word from each current label.

  • Wegovy: to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity; adults with overweight in the presence of at least one weight-related comorbid condition.
  • Trulicity: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
  • Saxenda: Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.
  • Victoza: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus,
  • Mounjaro: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Published results

What the largest trials on teens and children found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

STEP TEENS

Semaglutide · 201 people · Better than the comparison · Placebo-controlled randomized trial

At week 68, BMI fell 16.1% on semaglutide against a rise of 0.6% on placebo in adolescents with obesity. Stomach side effects were more common (62% against 42%), and 4% on semaglutide had gallstones against none on placebo.

N Engl J Med, 2022 (pubmed.ncbi.nlm.nih.gov/36322838)

The registry

Trials on teens and children, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide24413
Liraglutide1470
Exenatide1270
Tirzepatide623
Dulaglutide512
Mazdutide201
Orforglipron202
Posted results

What trials on teens and children reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT02918279Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With ObesityLiraglutidePhase 3251Change in BMI SDS (Week 0, Week 56) (SDS score), Week 0, week 56. Liraglutide 3.0 mg: -0.25; Placebo: -0.02.
NCT04102189A Research Study on How Well Semaglutide Works in Adolescents With Overweight or ObesitySemaglutidePhase 3201Change in Body Mass Index (BMI) (Percentage [%]) (Percentage change of BMI), Baseline (week 0), week 68. Semaglutide 2.4 mg: -16.2; Placebo: -0.1.
AWARD-PEDSA Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 DiabetesDulaglutidePhase 3154Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 (percentage of HbA1C), Baseline, Week 26. Placebo: 0.5; Pooled Dulaglutide: -0.7.
Ellipse™Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 DiabetesLiraglutidePhase 3135Change in HbA1c (Glycosylated Haemoglobin) (Percentage of HbA1c), Week 0, week 26. Liraglutide 1.8 mg: -0.643; Placebo: 0.415.
PIONEER TEENSA Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 DiabetesSemaglutidePhase 3132Change From Baseline (Week 0) to Week 26 in Glycosylated Haemoglobin (HbA1c)- Percentage Point (Percentage point), Baseline (Week 0), Week 26. Oral Semaglutide: -1.0; Placebo: -0.3.
NCT00658021Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 DiabetesExenatidePhase 3122Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28 (percentage (%HbA1c)), Baseline (Day 1) and Week 28. Total Exenatide Twice Daily (EBID): 0.11; Placebo: 0.38.
SURPASS-PEDSA Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or BothTirzepatidePhase 399Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (percentage of HbA1c), Baseline, Week 30. Pooled Doses of Tirzepatide (5 mg, 10 mg): -2.03; Placebo: -0.23.
APPLELiver and Fat Regulation in Overweight Adolescent GirlsExenatidePhase 2/392Hepatic Glucose Release (mg/kg/min), Measured up to 4 months from enrollment. Control: 1.85; PCOS Medication Naive: 1.46; PCOS, Medication Naive + Byetta: 1.54; PCOS on COCPs: 1.88; PCOS on Metformin: 1.57.
NCT01554618Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 DiabetesExenatidePhase 384Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period) (percentage (% HbA1c)), Baseline (Week 0) and Week 24. Controlled Assessment Period - Exenatide: -0.36; Controlled Assessment Period - Placebo: 0.49.
NCT04775082SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityLiraglutidePhase 382Relative Change in Body Mass Index (BMI) (Percentage (%) change of BMI), Baseline (week 0), week 56. Liraglutide 3.0 mg: -6.7; Placebo: 2.1.
TEALTreating PCOS With Semaglutide vs Active Lifestyle InterventionSemaglutidePhase 2/360Change in Hepatic Fat Fraction (Change in percentage of liver fat), Baseline and 12 weeks. Diet Intervention: -1.41; GLP-1 Intervention: -1.84.
NCT02527200Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeLiraglutidePhase 356Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks (SDS score), Week 0, Week 16. Part A: Liraglutide: -0.18; Part A: Placebo: -0.18; Part B: Liraglutide: -0.50; Part B: Placebo: -0.48; Part A+B: Liraglutide: -0.33; Part A+B: Placebo: -0.29.
NCT02516657Liraglutide in Adolescents With Type 1 DiabetesLiraglutidePhase 35On ClinicalTrials.gov (clinicaltrials.gov)
QUESTLifestyle Counseling and Medication for Adolescent Weight ManagementSemaglutidePhase 2121Percent Change in Body Mass Index (% change in body mass index (BMI)), Randomization to Week 56. Intensive Behavioral Program Arm: -1.8; Medication Arm: -22.3.
NCT02496611Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe ObesityExenatidePhase 2100Body Mass Index (percentage (body mass index)), 52 weeks. Weight Loss Maintenance Without Pharmacotherapy: 10.1; Weight Loss Maintenance With Pharmacotherapy: 4.6.
NCT04883346Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve GastrectomyLiraglutidePhase 234On ClinicalTrials.gov (clinicaltrials.gov)
NCT01237197Exenatide in Extreme Pediatric ObesityExenatidePhase 226Percent Change From Baseline in Body Mass Index at 3-months (percentage of change in BMI), Baseline and 3-months. Exenatide: -2.9; Placebo Injection: -0.15.
NCT02960659Title: Therapeutic Targets in African-American Youth With Type 2 DiabetesLiraglutidePhase 1/224Change in Absolute Gluconeogenesis From Baseline to 12 Weeks (mg/kg LBM/min), Baseline to 12 weeks. Metformin: 0.018; Metformin and Liraglutide: -0.050.
NCT00886626GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese ChildrenExenatidePhase 212Change in Body Mass Index (BMI) (change in kg/m^2), 3-month. Exenatide: -0.9; Control: 0.84.
NCT05696847A Study of Tirzepatide (LY3298176) in Pediatric Participants With ObesityTirzepatidePhase 128Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) (Percentage of participants), Baseline through Week 14, TEAE. Cohort 1: Placebo (BW >=50 kg): 0.0; Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg): 83.3; Cohort 2: Placebo (BW <50 kg): 0.0; Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg): 85.7; Cohort 3: Placebo (BW 40 to 60 kg): 33.3; Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg): 100.0.
NCT01444898Effects of Exenatide on Overweight Adolescents With Prader-Willi SyndromeExenatideNot phased10On ClinicalTrials.gov (clinicaltrials.gov)
Recruiting now

Trials on teens and children taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (clinicaltrials.gov/study/NCT07253285)SemaglutidePhase 3Sep 20, 2033
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) (clinicaltrials.gov/study/NCT06439277)TirzepatidePhase 3Dec 2030
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight (clinicaltrials.gov/study/NCT07255209)MazdutidePhase 3Oct 31, 2028
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes (clinicaltrials.gov/study/NCT07668336)DulaglutidePhase 3Mar 2030
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities (clinicaltrials.gov/study/NCT06672939)OrforglipronPhase 3Jan 2031
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) (clinicaltrials.gov/study/NCT07817875)TirzepatidePhase 3Dec 2032
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth (clinicaltrials.gov/study/NCT06934655)SemaglutidePhase 3Nov 1, 2033
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) (clinicaltrials.gov/study/NCT06672549)OrforglipronPhase 3Mar 2027
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (clinicaltrials.gov/study/NCT07282613)SemaglutidePhase 3Mar 30, 2030
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome (clinicaltrials.gov/study/NCT05819853)SemaglutidePhase 3Jun 30, 2028
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) (clinicaltrials.gov/study/NCT06739122)DulaglutidePhase 3Dec 2027
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity (clinicaltrials.gov/study/NCT06852391)SemaglutidePhase 4Dec 31, 2027
Semaglutide in Youth With Autism Spectrum Disorder (clinicaltrials.gov/study/NCT07770152)SemaglutidePhase 4Sep 1, 2029
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy (clinicaltrials.gov/study/NCT06903923)SemaglutidePhase 2Apr 30, 2030
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study (clinicaltrials.gov/study/NCT07874828)TirzepatidePhase 2Dec 31, 2036

The 15 largest of 21 recruiting.

From PubMed

Newest papers on GLP-1s and teens and children

  • Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43035096)

    Randomized trial · JAMA · Nov 15, 2026 · Kelly AS et al.

  • Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA) (pubmed.ncbi.nlm.nih.gov/42618811)

    Randomized trial · Diabetologia · Aug 19, 2026 · Adly AAM et al.

  • GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles (pubmed.ncbi.nlm.nih.gov/42401410)

    Meta-analysis · Pharmacol Res · Jul 4, 2026 · Li Y et al.

  • GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety (pubmed.ncbi.nlm.nih.gov/42365860)

    Systematic review · Diabetes Res Clin Pract · Jun 28, 2026 · Soliman AT et al.

  • The GLP-1 Agonist Exenatide Is Associated with Improved Adherence to Health Behavior and Lifestyle Treatment in Adolescents with Obesity: A Randomized Controlled Trial (pubmed.ncbi.nlm.nih.gov/42228680)

    Randomized trial · Obes Facts · Jun 2, 2026 · Stenlid R et al.

  • Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study (pubmed.ncbi.nlm.nih.gov/41296499)

    Randomized trial · Diabetes Care · Jun 1, 2026 · Arslanian S et al. · cited by 5

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on teens and children

  • TrialResults posted for a Liraglutide study: SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (clinicaltrials.gov/study/NCT04775082)
  • TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide in Youth With Autism Spectrum Disorder (clinicaltrials.gov/study/NCT07770152)
  • TrialResults posted for a Semaglutide study: Lifestyle Counseling and Medication for Adolescent Weight Management (clinicaltrials.gov/study/NCT04873245)
  • TrialNew Semaglutide study registered: Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity (clinicaltrials.gov/study/NCT07911046)
  • TrialNew Tirzepatide study registered: PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study (clinicaltrials.gov/study/NCT07874828)
  • TrialNew Semaglutide study registered: SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years (clinicaltrials.gov/study/NCT07845994)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and teens and children: common questions

What did the largest trial on teens and children find?

STEP TEENS (Semaglutide, 201 people): At week 68, BMI fell 16.1% on semaglutide against a rise of 0.6% on placebo in adolescents with obesity. Stomach side effects were more common (62% against 42%), and 4% on semaglutide had gallstones against none on placebo.

Is any GLP-1 FDA approved for teens and children?

Yes: Wegovy, Trulicity, Saxenda, Victoza and Mounjaro. Wegovy's label: to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity; adults with overweight in the presence of at least one weight-related comorbid condition.

Does insurance cover a GLP-1 for teens and children?

Plans decide, and they usually tie coverage to a medicine's approved uses, so Wegovy, Trulicity, Saxenda, Victoza and Mounjaro are the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.

Which GLP-1 has been studied most for teens and children?

Semaglutide, with 24 registered trials on it, then Liraglutide with 14. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for teens and children?

21 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.